


COPENDING APPLICATIONS

§ 1.98(a)(2) Content of information disclosure statement: Section 1.98(a)(2)(iii) requires submission of copies of U.S. patent applications that are being cited in IDS statements.

§ 1.98(d)(2) If a U.S. application was cited in an IDS prior to the effective date of the change to § 1.98(a)(2) (now requiring a copy of the cited application) but a copy of the cited application was not supplied, as was permissible under the former rule, a copy of the cited application must be supplied if cited in any continuing application where the citation is made after the effective date of the changes to §§ 1.98(a) and (d).



| <u>Attv. Docket No.</u> | <u>Serial Number</u> | <u>Inventor(s)</u> | <u>Filing Date</u> |
|-------------------------|----------------------|--------------------|--------------------|
| 7996P | 60/193,846 | deLong et al | 3/31/2000 |
| 7998P | 60/193,645 | deLong et al | 3/31/2000 |
| 7999P | 60/193,844 | deLong et al | 3/31/2000 |
| 8191 | 09/633,180 | deLong | 8/4/2000 |

Continued

Ex: L. Channavajjala

4/17/02

| | | |
|--|-----------------------|-------------------------|
| LIST OF DOCUMENTS CITED BY APPLICANTS (Use several sheets if necessary) | ATTY. DOCKET NO. 7997 | SERIAL NO. not assigned |
| | APPLICANT DeLong | |
| | FILING DATE 1/31/2001 | GROUP not assigned |

U. S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|---------------------|--------------------|----------|------------------|------------|--------------|-------------------------------|
| | US 3,435,053 | 3/25/69 | Beal et al | 260/345.2 | - | |
| | US 3,524,867 | 8/18/70 | Beal et al | 260/345.2 | - | |
| | US 3,598,858 | 8/10/71 | Bergstrom et al | 260/488.0 | - | |
| | US 3,691,218 | 9/12/72 | Bergstrom et al | 260/488 R | 260/488R | |
| | US 3,708,789 | 12/18/72 | Bergstrom et al | 260/488 D | 260/211R | |
| | US 3,778,938 | 12/4/73 | Bergstrom et al | 260/488 D | - | |
| | US 3,778,939 | 12/4/73 | Bergstrom et al | 260/488 D | - | |
| | US 3,839,409 | 10/1/74 | Bergstrom et al | 260/488 D | - | |
| | US 3,852,337 | 12/3/74 | Bergstrom et al | 260/488.R | 260/410 | |
| | US 3,882,241 | 5/6/75 | Pharries, BB | 424/305 | 424/318 | |
| | US 3,882,245 | 5/6/75 | DuCharme, DW | 424/318 | 424/305 | |
| | US 3,896,156 | 7/22/75 | Beal et al | 260/488D | 260/211 | |
| | US 3,928,588 | 12/23/75 | Robert, A | 424/234 | 424/273 | |
| | US 3,986,792 | 8/29/76 | Hayashi et al | 260/488D | 260/210R | |
| | US 3,984,455 | 10/5/76 | Beal et al | 260/488D | 260/247.2R | |
| | US 4,011,262 | 3/8/77 | Hess et al | 260/520B | 260/240R | |
| | US 4,024,179 | 5/17/77 | Bindra et al | 260/473A | 260/240R | |
| | US 4,081,671 | 12/6/77 | Beck et al | 260/514D | 260/343.3R | |
| | US 4,073,934 | 2/14/78 | Siubella et al | 424/305 | 260/295R | |
| | US 4,089,885 | 5/16/78 | Husbande, GEM | 260/448.8R | 260/514D | |
| | US 4,123,441 | 10/31/78 | Johnson, RA | 260/345.2 | 424/283 | |
| | US 4,128,720 | 12/5/78 | Hayashi et al | 560/8 | 260/327M | |
| | US 4,158,887 | 6/19/79 | Axon, UF | 260/413 | 260/346.22 | |
| | US 4,225,507 | 9/30/80 | Sh, JC | 260/348.22 | 260/345.2 | |
| | US 4,225,508 | 9/30/80 | Sh, JC | 260/348.22 | 260/345.2 | |
| | US 4,284,846 | 8/18/81 | Vorbruggen et al | 424/305 | 260/340.5P | |
| | US 4,489,082 | 12/18/84 | Vorbruggen et al | 424/304 | 260/345.7P | |
| | US 4,499,293 | 2/12/85 | Johnson et al | 549/485 | 548/252 | |
| | US 4,821,100 | 11/4/86 | Lund et al | 514/573 | 514/155 | |
| | US 4,704,388 | 11/3/87 | Mueller, RA | 514/211 | 540/547 | |
| | US 4,889,845 | 12/26/89 | Ritter et al | 514/83 | 514/573 | |
| | US 5,063,057 | 11/5/91 | Spellman et al | 424/401 | 208/528 | |
| | US 5,219,885 | 8/15/93 | Frolich et al | 514/530 | - | |
| | US 5,280,018 | 1/18/94 | Ritter et al | 514/83 | 424/47 | |
| | US 5,340,813 | 8/23/94 | Klein et al | 514/263 | 544/272 | |
| | US 5,422,371 | 6/6/95 | Liao et al | 514/580 | 514/703 | |
| | US 5,464,868 | 11/7/95 | Frolich et al | 514/530 | - | |
| | US 5,508,303 | 4/16/96 | Isogaya, et al | 514/488 | 549/458 | |
| | US 5,516,652 | 5/14/96 | Abramovitz et al | 435/69.1 | 435/240.1 | |
| | US 5,567,079 | 10/22/96 | Felder, A | 405/80 | 405/74 | |
| | US 5,576,315 | 11/19/96 | Hallinan et al | 514/211 | 540/547 | |
| | US 5,578,640 | 11/26/96 | Hanson, WR | 514/530 | 514/573 | |
| | US 5,578,643 | 11/26/96 | Henson, WR | 514/573 | 514/530 | |
| | US 5,605,814 | 2/25/97 | Abramovitz et al | 435/69.1 | 435/252.3 | |
| | US 5,605,931 | 2/25/97 | Hanson, WR | 514/530 | 514/573 | |
| | US 5,658,897 | 8/17/97 | Burk, RM | 514/118 | 546/22 | |
| | US 5,663,203 | 9/2/97 | Ekerdt et al | 514/572 | 514/573 | |
| | US 5,670,506 | 9/23/97 | Leigh et al | 514/258 | 514/283 | |

Ex 1 L. Channavajjala

4/17/02

| | | | | | | |
|--|--------------|-----------|-----------------------|----------|-----------|--|
| | US 5,681,850 | 10/28/87 | Frolich et al | 514/530 | -- | |
| | US 5,703,108 | 12/30/87 | Cameron et al | 514/382 | 514/304 | |
| | US 5,719,140 | 2/17/98 | Chandrakumar et al | 514/211 | 540/547 | |
| | US 5,759,789 | 6/2/98 | Abramovitz et al | 435/7.21 | 435/89.1 | |
| | US 5,770,759 | 6/23/98 | U no et al | 560/53 | 560/121 | |
| | US 5,792,851 | 8/11/98 | Schuster et al | 536/23.5 | 435/89.1 | |
| | US 5,840,847 | 11/24/98 | Abramovitz et al | 530/350 | 435/89.1 | |
| | US 5,834,488 | 11/10/98 | Burk, RM | 514/445 | 514/438 | |
| | US 5,869,281 | 2/9/1999 | Abramovitz et al | 435/89.1 | 435/252.3 | |
| | US 5,877,211 | 3/2/1999 | Woodward | 514/530 | 514/573 | |
| | US 5,885,786 | 3/23/1999 | Mahe et al | 435/1.1 | 435/29 | |
| | US 5,885,974 | 3/23/1999 | Danielov, MM | 514/108 | 514/103 | |
| | US 5,889,052 | 3/30/1999 | Klimko, et al | 514/530 | 514/573 | |
| | US 5,892,099 | 4/6/1999 | Maruyama, et al | 560/121 | 560/15 | |
| | US 5,958,723 | 8/28/1999 | Abramovitz et al | 435/89.1 | 536/23.5 | |
| | US 5,972,965 | 10/26/99 | Taniguchi et al | 514/328 | 514/374 | |
| | US 5,973,002 | 10/26/99 | Frolich et al | 514/530 | 514/530 | |
| | US 5,977,173 | 11/2/99 | Wos et al | 514/530 | 514/562 | |
| | US 5,985,597 | 11/16/99 | Ford-Hutchinson et al | 435/89.1 | 435/252.3 | |
| | US 5,990,348 | 11/23/99 | Kataoka et al | 562/503 | 549/422 | |
| | US 5,994,387 | 11/30/99 | Selliah et al | 514/473 | 549/475 | |
| | US 6,013,823 | 1/11/00 | Mamarella et al | 556/443 | -- | |
| | US 6,025,375 | 2/15/00 | Taniguchi et al | 514/374 | 548/238 | |
| | US 6,025,382 | 2/14/00 | Selliah et al | 514/473 | 549/475 | |
| | US 6,030,958 | 2/28/00 | Tremont et al | 514/63 | 556/418 | |
| | US 6,030,999 | 2/28/00 | Stjemachantz et al | 514/530 | -- | |
| | US 6,031,001 | 2/28/00 | Stjemachantz et al | 514/573 | -- | |
| | US 6,031,079 | 2/28/00 | Ford-Hutchinson et al | 530/350 | 435/89.1 | |
| | US 6,037,364 | 3/14/00 | Burk, RM | 514/438 | 514/461 | |
| | US 6,037,388 | 3/14/00 | Podos et al | 514/530 | 514/573 | |
| | US 6,043,264 | 3/28/00 | Ohtake et al | 514/374 | 514/444 | |

FOREIGN PATENT DOCUMENTS

| DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | TRANSLATION YES NO |
|-----------------|----------|----------------|-------|-----------|--------------------|
| BE 746615 | 7/31/70 | Belgium | A61K | | X |
| DE 1617477 | 1/8/70 | Germany | A61K | | X |
| DE 2460990 | 12/21/74 | Germany | C07C | 177/00 | X |
| EP 249194 | 6/9/86 | EPO | A61K | 31/557 | |
| EP 848488 | 10/13/83 | EPO | A61K | 31/00 | X |
| EP 911321 | 4/28/89 | EPO | C07C | 311/13 | |
| EP 925787 | 6/30/89 | EPO | A61K | 31/557 | |
| EP 970697 | 9/16/99 | EPO | A61K | 31/557 | |
| EP 947500 | 10/6/99 | EPO | C07C | 233/25 | |
| EP 1008588 | 2/10/98 | EPO | C07C | 405/00 | |
| EP 1016660 | 9/07/98 | EPO | C07D | 208/42 | |
| FR 2,108,027 | 9/27/71 | FRANCE | A61K | 7/00 | X |
| FR 2,730,811 | 2/27/85 | FRANCE | G01N | 33/48 | X |
| GB 1251750 | 10/27/71 | GREAT BRITAIN | C07C | 61/32 | |
| GB 1285371 | 8/16/72 | GREAT BRITAIN | A61K | 27/00 | |
| GB 1285372 | 8/16/72 | GREAT BRITAIN | C07C | 61/32 | |
| GB 1456512 | 11/24/76 | GREAT BRITAIN | C07C | 177/00 | |
| GB 1456513 | 11/24/76 | GREAT BRITAIN | C07D | 307/93 | |
| GB 1456514 | 11/24/76 | GREAT BRITAIN | C07F | 9/40 | |
| GB 2048254 | 12/10/80 | UNITED KINGDOM | C07C | 177/10 | |
| GB 2330307 | 4/21/89 | UNITED KINGDOM | A61K | 31/557 | |
| JP 3-83,925 | 4/9/91 | JAPAN | A61K | 31/557 | X |
| JP 3-83,926 | 4/9/91 | JAPAN | A61K | 31/557 | X |
| JP 4-300,833 | 10/23/92 | JAPAN | A61K | 31/557 | X |
| JP 9-295,921 | 11/18/97 | JAPAN | A61K | 7/06 | X |

Ex: L Channasijala

4/17/02

| | | | | | | | |
|--|---------------|-----------|-------|-------|--------|---|--|
| | JP 10-287,532 | 10/27/98 | JAPAN | A61K | 7/08 | X | |
| | JP 49-101,356 | 8/25/74 | JAPAN | 16C86 | - | X | |
| | JP 49-102,647 | 9/27/74 | JAPAN | 16C88 | - | X | |
| | JP 61-218,510 | 9/29/86 | JAPAN | A61K | 7/08 | X | |
| | WO 00/2450 | 1/20/2000 | PCT | A01N | 37/08 | | |
| | WO 00/3736 | 1/27/2000 | PCT | A61K | 47/44 | | |
| | WO 00/3980 | 1/27/2000 | PCT | C07C | 405/00 | | |
| | WO 00/4888 | 2/3/2000 | PCT | A61K | 31/215 | | |
| | WO 00/4899 | 2/3/2000 | PCT | A61K | 31/215 | | |
| | WO 00/9557 | 2/24/2000 | PCT | C07C | 14/47 | | |
| | WO 00/13864 | 3/16/2000 | PCT | A61K | 47/36 | | |
| | WO 00/15608 | 3/23/2000 | PCT | C07C | 405/00 | | |
| | WO 00/16780 | 3/30/2000 | PCT | A61K | 31/00 | | |
| | WO 86/00616 | 1/30/1986 | PCT | C07D | 239/02 | | |
| | WO 84/08585 | 4/28/84 | PCT | A61K | 31/557 | | |
| | WO 95/00552 | 1/5/95 | PCT | C07K | 13/00 | | |
| | WO 95/11003 | 4/27/95 | PCT | A61K | 7/42 | | |
| | WO 95/11033 | 4/27/95 | PCT | A61K | 33/24 | | |
| | WO 95/19964 | 7/27/95 | PCT | C07C | 405/00 | | |
| | WO 98/10407 | 4/11/96 | PCT | A61K | 31/557 | | |
| | WO 97/09049 | 3/13/97 | PCT | A61K | 31/557 | | |
| | WO 97/15319 | 5/1/97 | PCT | A61K | 38/18 | | |
| | WO 97/23223 | 7/3/97 | PCT | A61K | 31/557 | | |
| | WO 97/23225 | 7/3/97 | PCT | A61K | 31/557 | | |
| | WO 97/23226 | 7/3/97 | PCT | A61K | 31/557 | | |
| | WO 97/28735 | 8/21/97 | PCT | A61K | 7/42 | | |
| | WO 97/39754 | 10/30/97 | PCT | A61K | 31/557 | | |
| | WO 98/00100 | 1/8/98 | PCT | A61K | 7/42 | | |
| | WO 98/12175 | - | PCT | C07C | 405/00 | | |
| | WO 98/13016 | 4/02/98 | PCT | A61K | 7/42 | | |
| | WO 98/19680 | 5/14/98 | PCT | A61K | 31/557 | | |
| | WO 98/20880 | 5/22/98 | PCT | A61K | 31/557 | | |
| | WO 98/20881 | 5/22/98 | PCT | A61K | 31/557 | | |
| | WO 98/21180 | 5/22/98 | PCT | C07C | 405/00 | | |
| | WO 98/21181 | 5/22/98 | PCT | C07C | 405/00 | | |
| | WO 98/21182 | 5/22/98 | PCT | C07C | 405/00 | | |
| | WO 98/27978 | 7/2/98 | PCT | A61K | 31/18 | | |
| | WO 98/28264 | 7/2/98 | PCT | C07C | 311/08 | | |
| | WO 98/33497 | 8/6/98 | PCT | A61K | 31/215 | | |
| | WO 98/39283 | 9/11/98 | PCT | C07C | 405/00 | | |
| | WO 98/50024 | 11/12/98 | PCT | A61K | 31/215 | | |
| | WO 98/53809 | 12/3/98 | PCT | A61K | 31/215 | | |
| | WO 98/57830 | 12/23/98 | PCT | C07C | 405/00 | | |
| | WO 98/57942 | 12/23/98 | PCT | C07D | 307/20 | | |
| | WO 98/58911 | 12/30/98 | PCT | C07C | 405/00 | | |
| | WO 99/02165 | 1/21/99 | PCT | A61K | 31/557 | | |
| | WO 99/12550 | 3/18/99 | PCT | A61K | 31/557 | | |
| | WO 99/12551 | 3/18/99 | PCT | A61K | 31/557 | | |
| | WO 99/12895 | 3/18/99 | PCT | C07C | 405/00 | | |
| | WO 99/12896 | 3/18/99 | PCT | C07C | 405/00 | | |
| | WO 99/12897 | 3/18/99 | PCT | C07C | 405/00 | | |
| | WO 99/12898 | 3/18/99 | PCT | C07C | 405/00 | | |
| | WO 99/12898 | 3/18/99 | PCT | C07C | 405/00 | | |
| | WO 99/19300 | 4/22/99 | PCT | C07D | 213/71 | | |
| | WO 99/21562 | 5/6/99 | PCT | A61K | 31/557 | | |
| | WO 99/22731 | 5/14/99 | PCT | A61K | 31/44 | | |
| | WO 99/25357 | 5/27/99 | PCT | A61K | 31/557 | | |
| | WO 99/25358 | 5/27/99 | PCT | A61K | 31/557 | | |
| | WO 99/30675 | 6/24/99 | PCT | A61K | 7/08 | | |
| | WO 99/30718 | 6/24/99 | PCT | A61K | 31/557 | | |
| | WO 99/32441 | 7/1/99 | PCT | C07C | 405/00 | | |
| | WO 99/32640 | 7/1/99 | PCT | C12N | 15/62 | | |

L. Chamarajjala

4/17/02

| | | | | | | | |
|--|-------------|----------|-----|------|--------|--|--|
| | WO 99/32841 | 7/1/99 | PCT | C12N | 15/80 | | |
| | WO 99/33794 | 7/8/99 | PCT | C07C | 405/00 | | |
| | WO 99/47497 | 9/23/99 | PCT | C07C | 315/00 | | |
| | WO 99/50241 | 10/7/99 | PCT | C07C | 405/00 | | |
| | WO 99/50242 | 10/7/99 | PCT | C07C | 405/00 | | |
| | WO 99/61029 | 12/2/99 | PCT | A61K | 31/557 | | |
| | WO 99/64621 | 12/16/99 | PCT | C12Q | 1/25 | | |
| | WO 99/65303 | 12/23/99 | PCT | A01N | 37/08 | | |
| | WO 99/65527 | 12/23/99 | PCT | A61K | 47/10 | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----------------------------|---|
| | DeLong MA Prostaglandin receptor ligands: Recent patent activity. <i>Drugs</i> 2000 3(8): 1039-1052 |
| | Negishi, M.; Sugimoto, Y.; Ichikawa, A.; Molecular mechanisms of diverse actions of prostanoid receptors. <i>Biochimica et Biophysica Acta</i> 1259 1995 109-120. |
| | Collins, PW; Djuric SW; Synthesis of therapeutically useful prostaglandin and prostacyclin analogs <i>Chem. Rev.</i> 1993 93 1533-1584. |
| | Coleman RA, Kennedy I, Humphrey PPA, Bunce K, Lumley P Prostanoids and their receptors. <i>Comprehensive Medicinal Chemistry</i> , Vol. 3; Membranes and Receptors. 1990 843-714 |
| Unable to obtain reference | Coleman RA, Smith WL, Narumiya S <i>Pharmacol. Rev.</i> 1994 46 205-229. |
| | Albert Alm, MD The Potential of prostaglandin derivatives in glaucoma therapy; Prostaglandins and derivatives <i>Current Opinion in Ophthalmology</i> 1993 4(11) 44-50. |
| | Coleman RA, Smith WL, Narumiya S Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes <i>Pharmacological Reviews</i> 1994 46(2) 205-229. |
| | Kiyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells <i>British Journal of Pharmacology</i> 1997 (122) 217-224. |
| | Funk CD, Furci L, Fitzgerald GA, Cloning and expression of a cDNA for the human prostaglandin E receptor EP ₁ subtype <i>Journal of Biological Chemistry</i> 1993 (268) 26767-26772. |
| | Abramovitz M, Bole Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM and Grygorczyk R Cloning and expression of a cDNA for the human prostanoid FP receptor <i>Journal of Biological Chemistry</i> 1994 269 2832-2838. |
| | Ichikawa EA, Sugimoto Y, Negishi M Molecular aspects of the structures and functions of the prostaglandin E receptors <i>Journal of Lipid Mediators Cell Signalling</i> 14 1996 63-87. |
| | Krauss AHP, Woodward DF, Gibson LL, Protzman CE, Williams LS, Burk RM, Gac TS, Roof MB, Abbas F, Marshall K, Senior J Evidence for human thromboxane receptor heterogeneity using a novel series of 8,11-cyclic carbonates derivatives of prostaglandin-F ₂ -alpha <i>British Journal of Pharmacology</i> 1996 117(6) 1171-1180. |
| | Corsini A, Folco GC, Fumagalli R, Nicolis S, Noe MA, Oliva O (5Z)-Carbacyclin discriminates between prostacyclin receptors coupled to adenylyl cyclase in vascular smooth muscle and platelets <i>British Journal of Pharmacology</i> 1997 90 255-261. |
| Unable to obtain reference | Woodward DF, Gil DW, Chen J, Burk RM, Kedzie KM, Krauss AHP Emerging evidence for additional prostanoid receptor subtypes <i>Cur. Top. Pharmacol.</i> 1998 4 153-162. |
| | Woodward DF, Madhu C, Rix P, Khariamb A Studies on the ocular effects of a pharmacologically novel agent prostaglandin F ₂ alpha 1-OCH ₃ (AGN 191129) <i>N-S Archives of Pharmacology</i> 1996 358 (1). P1713 |
| | Orlicky DJ Negative regulatory activity of a prostaglandin F ₂ receptor associated protein (FPRP) <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> 1996 54(4) 247-259. |

Ex: L. Channavajjala

4/17/02

| | |
|----------------------------|---|
| | Jakobsson PJ, Morgenstern R, Mancini J, Ford-Hutchinson A, Persson B Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG)-A widespread protein superfamily <i>Am. J. Resp. Crit. Care Med.</i> 2000 (161) S20-S24. |
| | Abramovitz M, Adam M, Boie Y, Carriere MC, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Garsau Y, Ruel R, Juteau H, Labelle M, Ouhmet N, Metters KM The utilization of recombinant prostanoicd receptors to determine the affinities and selectivities of prostaglandins and related analogs <i>Biochimica et Biophysica Acta</i> 2000 1483 (2) 285-293. |
| | Ruel R, Lacombe P, Abramovitz M, Godbout C, Lamontagne S, Rochette C, Sawyer N, Saccoo R, Tremblay NM, Metters KM, Labelle M New class of biphenylene dibenzazocinones as potent ligands for the human EP ₁ prostanoicd receptor <i>Bioorganic & Medicinal Chemistry Letters</i> . 1999 (9) 2699-2704. |
| | Hallinan EA, Hagen TJ, Tsymbalov S, Huss RK, Lee AC, Staplefield A, Savage MA Aminoacyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE ₂ antagonist, and its analogs <i>J. Med. Chem.</i> 1998 39 809-813 |
| Unable to obtain reference | Pharmaprojects No.6321 |
| | Maruyama T, Koketsu M, Yamamoto H, Yamamoto K, Yamamoto L T, Hayashida K I, Ohuchida S, Kondo K EP ₁ receptor antagonists suppress tactile allodynia in rats <i>Prostaglandins Lipid Mediat.</i> 1998 59 217. |
| Unable to obtain reference | ADIS, ADISINSIGHT: ZD-6416-Mar-27-2000. |
| | Ueda K, Saito A, Nakano H, Aoshima M, Yokota M, Murakami R, Iwata T Brief clinical and laboratory observations: Cortical hyperostosis following long-term administration of prostaglandin E ₁ in infants with cyanotic congenital heart disease <i>The Journal of Pediatrics</i> 1999 87 834-838. |
| | Shih MS, Nordin RW PGE ₂ induces regional remodeling changes in Haversian envelope: A histomorphometric study of fractured ribs in beagles <i>Bone and Mineral</i> 1996 (1) 227-234. |
| | Mori S, Jee WSS, Li XJ, Chan S, Kimmel DB Effects of prostaglandin E ₂ on production of new cancellous bone in the axial skeleton of ovariectomized rats <i>Bone</i> 1999 (11) 103-113. |
| | Chyun YS, Raisz LG Stimulation of bone formation by prostaglandin E ₂ <i>Prostaglandins</i> 1984 (27) 87-103. |
| | Nordin RW, Jee WSS, High WB The role of prostaglandins in bone in vivo <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> 1999 (41) 139-148. |
| | Roof SL, deLong MA, Charest RP mRNA expression of prostaglandin receptors EP ₁ , EP ₂ , EP ₃ , and EP ₄ in human osteoblast-like cells and 23 human tissues <i>Journal Bone Min. Res.</i> 1996 (11) S337. |
| | Hartke JR, Janikowsky ML, deLong MA, Soehner ME, Jee WSS, Lundy MW Prostanoid FP agonists build bone in the ovariectomized rat <i>J. Bone Min. Res.</i> 1999 (14) T326, pg S207. |
| | Lundy MW, deLong MA, Combs KS, Groes GJ, Soehner ME, Hartke JR Restoration of cancellous architecture and increased bone strength in aged osteopenic rats treated with fluprostenol <i>J. Bone Min. Res.</i> 1999 1(4) SA368, pg S401. |
| | Wang Y, Woo JA, Dirr MA, Soper DL, deLong MA, Mieling G, De B, Amburgey J, Suchanek E, Taylor CJ The design and synthesis of 13, 14- dihydro prostaglandin F _{2a} analogs as potent and selective ligands for the human FP receptor. <i>J. Med. Chem.</i> 2000 43(5) 845-852. |
| | Sakuma Y, Tanaka K, Suda M, Yasoda A, Natsui K, Tanaka I, Ushikubi F, Narumiya S, Segi E, Sugimoto Y, Ichikawa A, Nakao K Crucial involvement of the EP ₂ subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide <i>J. Bone and Mineral Research</i> . 2000 15(2) 218-227. |

Exp: L. Chennavajjala

4/17/02

| | |
|----------------------------|---|
| Unable to obtain reference | DeToro F Jr, Sylvia VL, Schubkegel SR, Campos R, Dean DD, Boyen BD, Schwartz Z Characterization of prostaglandin E ₂ receptors and their role in 34,25-(OH) ₂ D ₃ -mediated effects on resting zone chondrocytes <i>J. Cell. Physiol.</i> 2000 182(2) 196-208. |
| | Narumiya S Roles of prostanoids in health and disease, lessons from receptor-knockout mice <i>Int. Congr. Ser.</i> 1999 1181 261-269 |
| | Audoly LP, Tilley J, Goulet J, Key M, Nguyen M, Stock JL, McNeish JD, Koller BH, Coffman TM Identification of specific EP receptors responsible for the hemodynamic effects of PGE ₂ <i>Am. J. Physiol.</i> 1999 46(3) H824-830. |
| | Vayssairat M Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis <i>J. Rheumatol.</i> 1998 26(10) 2173-2178. |
| | Murakami T, Sawada K, Taneda K, Hayashi M, Katsura Y, Tanabe H, Kyoki M, and Araki H. Effect of isocarbocyclic methyl ester incorporated in lipid microspheres on experimental models of peripheral obstructive disease. <i>Arzneim.-Forsch./Drug Res.</i> 1996 45(II) Nr. 9, pg 991-994. |
| | Hall A, Smith WHT Clinprost Telfin <i>Current Opinion in Cardiovascular, Pulmonary & Renal Investigations Drugs</i> 1998 1(5) 605-610. |
| | Taneda N, Yamakoshi T, Hasegawa M, Tanikawa H, Negata H, Masako KI, Konno A Effect of a thromboxane A ₂ receptor antagonist, rametroban (BAY U3405), on inflammatory cells, chemical mediators and non-specific nasal hyperreactivity after allergen challenge in patients with perennial allergic rhinitis <i>Allergy International.</i> 1998 47(1), 59-67. |
| Unable to obtain reference | Miyamoto T, Takashima T A comparison in the efficacy and safety between rametroban (BAY u 3405) and omeprazole HCl for bronchial asthma: a phase III, multi-center, randomized, double-blind, group comparative study <i>Fincho Jyaku.</i> 1997-73 589-639. |
| | Rampton DS, Carty E, Van Nuster L Anti-inflammatory profile in vitro of ridogrel, a putative new treatment for inflammatory bowel disease <i>Gastroenterology</i> 1999 (116)G3477, pg 801. |
| | McCullough PA Ridogrel (Janssen) <i>Current Opinion in Anti-inflammatory & Immunomodulatory Investigational Drugs</i> 1999 1(3), 265-278. |
| | Inoue H Thromboxane A ₂ receptor antagonists <i>Farumashia</i> 1998 32(10) 1221-1226. |
| | Lardy C, Rousselet C, Chavemac G, Depin JC, Guenier D Antiaggregant and antithrombotic properties of the new thromboxane A ₂ receptor antagonist sodium 4-[[1-[[[4-(4-chlorophenyl) sulfonyl]amino] methyl] cyclopentyl] methyl] benzenesulfonate <i>Arzneim.-Forsch./Drug Res.</i> 1996 44(11) 1196-1202. |
| | Cayatte AJ, Du Y, et al The thromboxane A ₂ receptor antagonist, S18888, decreases atherosclerotic lesions and serum intracellular adhesion molecule-1 in the Apo E knockout mouse <i>Circulation.</i> 1998 99 115. |
| Unable to obtain reference | Verbeuren TJ, Descombes JJ The TP-receptor antagonist S-18888 unmask vascular relaxation and potentiates the anti-platelet action of PGD ₂ <i>Thromb. Haemostasis.</i> 1997 693. |
| Unable to obtain reference | Yoshida K, Sato H Synthesis and pharmacological activities of the new TXA ₂ receptor-antagonist Z-339 and related compounds <i>AFMC</i> 1995 95 53. |
| | Kerstetter JR, Brubaker RF, Wilson SE, Kullerstrand LJ Prostaglandin F ₂ alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow <i>American Journal of Ophthalmology</i> 1988 105 30-34. |
| Unable to obtain reference | AGN-192024 <i>Pharmaprojects</i> Oct. 1998 FB4 S1G. |
| | VanDenburgh AM, Laibovitz RA, Felix C A one-month dose-response study of AGN 192024, a novel antiglaucoma agent, in patients with elevated intraocular pressure IOVS, 1999 40 (4) 4373-B176, pg S630. |

L. Channevayala

4/12/02

| | |
|----------------------------|--|
| | Chen J, Woodward DF, Gil DW, Messier T, Marshall K, Senior J AGN 181129: A neutral prostaglandin F-2 alpha (PGF _{2α}) analog that lacks the mitogenic and uterotonic effects typical of FP receptor agonists <i>IOVS</i> . 1999 40 3562-8420, pg S675. |
| | Sharif NA, Davis TL, Williams GW ³ H AL-5848 ([³ H]β beta-(*)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor <i>J. Phar. Pharmacol.</i> 1999 51(6) 885-94. |
| | Garadi R, Silver L, Landry T, Turner FD Travoprost: A new once-daily dosed prostaglandin for the reduction of elevated intraocular pressure <i>IOVS</i> . 1999 40(4) 4378-8181, pg S831. |
| | Dean TR, Barnes GE, Li B, Chandler ML Improvement of optic nerve head blood flow after one-week topical treatment with travoprost (AL-06221) in the rabbit <i>IOVS</i> . 1999 40(4) 2688-8563, pg S509 |
| | Griffin BW, Klimko P, Corder JY, Sharif NA AL-5819: a novel prostaglandin F _{2α} analog with selective antagonist effects at the prostaglandin F _{2α} (FP) receptor <i>J. Pharmacol. Exp. Ther.</i> 1999 280(3) 1278-1284. |
| | Woodward DF, Bogardus AM, Donello JE, Fairbairn CE, Gil DW, Kedzie KM, Burke JA, Kharlam A, Runde E Molecular characterization and ocular hypotensive properties of the prostanoid EP ₂ receptor <i>J. Oc. Pharm. Therap.</i> 1996 11(3) 447-454. |
| | Karim SMM, Adakin PG, Kotigoda SR Prostaglandins and human respiratory tract smooth muscle: Structure activity relationship <i>Adv. Prostaglandin Thromboxane Res.</i> 1990 7 968-980. |
| | Maw GN Pharmacological therapy for the treatment of erectile dysfunction <i>Annu. Rep. Med. Chem.</i> 1999 34 71-80. |
| | Anon. Alprostadil (naxamed): Alprox-TD, Befar, Femprox, prostaglandin E ₁ (naxamed) <i>Drugs R&D</i> 1999 2(8) 413-414. |
| Unable to obtain reference | Matsumura H Prostaglandins and sleep <i>Saishin-No to Shinkai Kagaku Shirin</i> 1999 10 79-89. |
| | Tomita Y, Maeda K, Tagami H Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation <i>Pigm. Cell Res.</i> 1992 5(5, Pt. 2) 367-81. |
| | Huang A, Katori M, Kawamura M, Li B, Harada Y Different modes of inhibition of increase in cytosolic calcium and aggregation of rabbit platelets by two thromboxane A ₂ antagonists <i>Asia Pacific Journal of Pharmacology</i> 1994 9 163-171 |
| | Flisiak R, Prokopowicz D Effect of misoprostol on the course of viral hepatitis B <i>Hepato-Gastroenterology</i> 1997 44(17) 1419-1425. |
| Unable to obtain reference | Mihale D, Cristea E, Mihale D, Cocu F The testing of the hepatoprotective action of some new synthetic prostaglandins <i>Farmacie (Bucharest)</i> 1999 47(5) 43-58. |
| | Vengerovsky AI, Baturina NO, Sarstikov AS Hepatoprotective action of prostaglandins <i>Eksp. Klin. Farmakol.</i> 1997 60(5) 78-82. |
| | Gissold D The potential for prostaglandin pharmaceuticals <i>Spec. Publ. - R. Soc. Chem.</i> 1999 244 115-129. |
| | Zimbric, M.L.; Cappas, A.A.; Uno, H.; Albert, D.M.; EFFECTS OF LATANOPROST OF HAIR GROWTH IN THE BALD SCALP OF STUMPTAILED MACAQUES. <i>IOVS</i> , 1999 (40) 3569-8427, pg S676 |
| | Voas, N.G.; Lindstrom, M.J.; Zimbric, M.L.; Albert, D.M.; Uno, H INDUCTION OF ANAGEN HAIR GROWTH IN TELOGEN MOUSE SKIN BY TOPICAL LATANOPROST APPLICATION. <i>IOVS</i> , 1999 (40) 3570-8428, pg S676 |
| | Johnstone, M.A Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. <i>American Journal of Ophthalmology</i> 1997 544-547 |
| | Eisenberg DL, Camras CB A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension. <i>Drug Safety</i> 1999 20(6), 505-514 |
| | Milikan LE, Treatment of Alopecia. <i>Journal Clinical Pharmacology</i> 1987 (27) no. 8, pg 715 |




L. Chamarajjala

4/17/02

| | |
|----------------------------|---|
| | Depperman, W.H. Jr.; Up-to-date scalp tonic. <i>New England Journal of Medicine</i> , (1970 Nov 12) 283 (20) 1115. |
| | Johnstone MA Brief latanoprost Rx induces hypertrichosis. <i>Invest</i> , (March 15, 1998) Vol. 39, No. 4, pg. S258 |
| Unable to obtain reference | Al-Saretti, M.R.; Abu-Amer, K.M.; Ser, P.; Al-Fateh University of Medical Sciences, Tripoli, Libya, <i>Indian J. Pharmacology of rosemary (rosmarinus officinalis Linn.) and its therapeutic potentials-Exp. Biol.</i> (1998), 37(2), 124-130. |
| | Olsen EA, and DeLong E. Transdermal viprostal in the treatment of male pattern baldness. <i>Journal of American Acad. Dermatology</i> , (1990) 23 (3 Part 1), 470-472. |
| | Houssay AB, Arias NH, Davison TA, and Epper CE Effects of prostaglandins upon hair growth in mice. <i>Acta Physiol. Lat. Am.</i> (1976), 288(3), 188-191 |
| | Millan LE Treatment of male pattern baldness. <i>Drug Therapy</i> 1989 19, No. 3, 62-73. |
| | Roanick HH New topical agents for hair growth. <i>Clinics in Dermatology</i> 1988 6 (4) 119-21. |
| | Vincent JE Prostaglandin synthesis and selenium deficiency a hypothesis. <i>Prostaglandins</i> , (1974) 8 (4), 339-340 |
| | Malkinson FD, Geng L, and Hanson W R. Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin. <i>Journal Invest. Dermatol.</i> (1989) 101 (1, Suppl.), 135e-137a. |
| | Jimenez JJ, Hussein AM, and Yunis AA. Stimulated monocyte-conditioned media protect from cytosine arabinoside-induced alopecia in rat. <i>Clin. Res.</i> (38, No. 4, 973a, (1990) |
| | Hanson, W.R.; Pelka, A.E.; Nelson, A.K.; and Malkinson, F.D.; Rush Medical Center, Chicago. 16,16 dm prostaglandin 2 protects from acute radiation-induced alopecia in mice. <i>Clin. Res.</i> (38, No. 6, 906a, 1990) |
| | Ling G, Hanson WR, Malkinson FD, 16,16 dm prostaglandin E2 protects mice from fractionated radiation-induced alopecia. <i>Clin. Res.</i> , 1988 36, No. 6, 906a |
| Unable to obtain reference | Hanson, W.R.; Geng, L.; and Malkinson, F. D.; Loyola and Hines Medical Centers, Maywood, IL. Prostaglandin-induced protection from radiation or doxorubicin is tissue specific in mice. <i>Journal of Investigative Dermatology</i> , (1998) vol. 106, No. 4, pg 858. |
| | Geng L, Malkinson FD, Hanson WR. Misoprostol, a PGE-1 analog that is radioprotective for murine intestine and hair, induces widely different cytokinetic changes in these tissues. <i>Journal of Investigative Dermatology</i> , (1998) Vol. 106, No. 4, Pg. 858. |
| | Geng L, Hanson WR, Malkinson FD, Topical or systemic 16,16 dm-prostaglandin E2 or WR-2721 (WR-1085) protects mice and alopecia after fractionated irradiation. <i>Int. Journal Radiat. Biol.</i> (1992), 61(4), 533-7. |
| | Hanson WR, Pelka AE, Nelson AK, Malkinson FD Subcutaneous or topical administration of 16,16 dimethyl prostaglandin E2 protects from radiation-induced alopecia in mice. <i>Int. Journal Radiat. Oncol., Biol. Phys.</i> (1992), 23(2), 333-7 |
| | Hulan HW, Kramer JKG. The effect of long-chain monoenes on prostaglandin E2 synthesis by rat skin. <i>Lipids</i> (1977), 12(7), 804-9 |
| | Hulan HW, Hunsaker WG, Kramer JKG, Mahadevan S. The development of dermal lesions and alopecia in male rats fed rapeseed oil. <i>Can. J. Physiol Pharmacol.</i> (1976) 54, (1), 1-8. |
| | Sredni B, Xu RH, et al The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models. <i>Int. J. Cancer</i> (1996), 65 (1), 97-103 |
| | Kvedar JC, Baden HP, Topical minoxidil in the treatment of male pattern alopecia. <i>Pharmacotherapy</i> 1987 (7) No. 6, 191-97 |
| | Hecker M; Ullrich,V; Studies on the interaction of minoxidil with prostacyclin synthase in-vitro. <i>Biochem. Pharmacol.</i> , (1988) 37(17), 3363-3365 |
| | Michalet JF, Commo S, Bilani N, Mahe YF, Bernard BA Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulation effect. <i>Journal of Investigative Dermatology</i> (1997), 108(2), 205-209. |
| | Lachgar S, Charveron M, Bouhaddiou N, Gail Y, Bonafe JL Modulation by minoxidil and VEGF of the production of inflammatory mediators by hair follicle dermal papilla cells. <i>Journal Invest. Dermatol.</i> 1995 104, No. 1, 161 |
| | Lachgar, S. Charveron, M.; et al; Hair dermal papilla cell metabolism is influenced by minoxidil. <i>Fundam. Clin. Pharmacol.</i> 1997 (11, No. 2) 178 |

L. Channasappa

4/17/02

| | |
|--|---|
| Unable to obtain reference | Lachgar, S. Charverson, M.; et al; Laboratoire Culture De Peau, Clinical and Bio-Clinical Research Group Dermatology, Toulouse, France. Effect of VEGF and minoxidil on the production of arachidonic acid metabolites by cultured hair, dermal papilla cells. <i>European Journal of Dermatol.</i> (1998), 6(5), 385-388 |
|  | Saul JJ, White JG, Wilkop CJ Influence of prostaglandin E-1 prostaglandin E-2 and arachidonate on melanosomes in melanocytes and keratinocytes of anagen bulbs in-vitro. <i>Journal Invest. Dermatol.</i> (1975) 64(5), 332-337 |
| EXAMINER |  |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | DATE CONSIDERED  |

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE